0001209191-20-051403.txt : 20200922 0001209191-20-051403.hdr.sgml : 20200922 20200922110947 ACCESSION NUMBER: 0001209191-20-051403 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200918 FILED AS OF DATE: 20200922 DATE AS OF CHANGE: 20200922 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burow Kristina CENTRAL INDEX KEY: 0001569248 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39512 FILM NUMBER: 201188399 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Metacrine, Inc. CENTRAL INDEX KEY: 0001634379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472297384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-369-7800 MAIL ADDRESS: STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-18 0 0001634379 Metacrine, Inc. MTCR 0001569248 Burow Kristina C/O ARCH VENTURE FUND VIII, L.P. 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 1 0 0 0 Common Stock 2020-09-18 4 C 0 1960784 A 1960784 I See footnote Common Stock 2020-09-18 4 C 0 472251 A 2433035 I See footnote Common Stock 2020-09-18 4 C 0 138734 A 2571769 I See footnote Common Stock 2020-09-18 4 P 0 210000 13.00 A 2781769 I See footnote Common Stock 2020-09-18 4 C 0 138734 A 138734 I See footnote Common Stock 2020-09-18 4 P 0 20000 13.00 A 158734 I See footnote Series A Convertible Preferred Stock 2020-09-18 4 C 0 1960784 D Common Stock 1960784 0 I See footnote Series B Convertible Preferred Stock 2020-09-18 4 C 0 472251 D Common Stock 472251 0 I See footnote Series C Convertible Preferred Stock 2020-09-18 4 C 0 138734 D Common Stock 138734 0 I See footnote Series C Convertible Preferred Stock 2020-09-18 4 C 0 138734 D Common Stock 138734 0 I See footnote Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. These shares are directly held by ARCH Venture Fund VIII, L.P., or ARCH Fund VIII. The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P., or ARCH Partners VIII, which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC, or ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The Reporting Person has an interest in ARCH Partners VIII and ARCH VIII LLC but does not have voting or investment control over the shares held by ARCH Fund VIII. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein. These shares are directly held by ARCH Venture Fund VIII Overage, L.P., or ARCH Fund Overage. The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The Reporting Person has an interest in ARCH VIII LLC but does not have voting or investment control over the shares held by ARCH Fund Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein. Kristina Burow, Managing Director By: /s/ Mark McDonnell, as Attorney-in-Fact 2020-09-22